Список литературы

1. The Non-Hodgkin's Lymphoma Classification Project. A clinical evaluation of the International Lymphoma Study Group classification of non-Hodgkin's lymphoma. Blood. 1997; 89(11): 3909 - 18.

2. Solal-Celigny P.; Roy P.; Colombat P. et al. Follicular lymphoma international prognostic index. Blood. 2004; 104: 1258 - 1265.

3. Buske C.; Hoster E.; Dreyling M.; Hasford J. et al. The Follicular Lymphoma International Prognostic Index (FLIPI) separates high risk from intermediate or low risk patients with advanced stage follicular lymphoma treated front-line with Rituximab and the combination of Cyclophosphamide, Doxorubicin, Vincristine and Prednisone (R-CHOP) with respect to treatment outcome. Blood. 2006; 108: 1504 - 1508.

4. Federico M.; Bellei M; Marcheselli L. et al. Follicular lymphoma international prognostic index 2: a new prognostic index for follicular lymphoma developed by the international follicular lymphoma prognostic factor project. J Clin Oncol. 2009; 27: 4555 - 4652.

5. Young R.C.; Longo D.L.; Glatstein E. et al. The treatment of indolent lymphomas: watchful waiting v aggressive combined modality treatment. Semin Hematol. 1988; 25(2 Suppl 2): 11 - 6.

6. Brice P.; Bastion Y.; Lepage E. et al. Comparison in low-tumor-burden follicular lymphomas between an initial no-treatment policy, prednimustine, or interferon alfa: a randomized study from the Groupe d'Etude des Lymphomes Folliculaires. Groupe d'Etude des Lymphomes de l'Adulte. J Clin Oncol. 1997; 15(3): 1110 - 7.

7. Friedberg J.W.; Taylor M.D.; Cerhan J.R. et al. Follicular lymphoma in the United States: first report of the national LymphoCare study. J Clin Oncol. 2009; 27(8): 1202 - 8.

8. Ardeshna K.; Qian W.; Smith P. et al. An Intergroup Randomised Trial of Rituximab Versus a Watch and Wait Strategy In Patients with Stage II, III, IV, Asymptomatic, Non-Bulky Follicular Lymphoma (Grades 1, 2 and 3a). A Preliminary Analysis. Blood (ASH Annual Meeting Abstracts). 2010; 116: Abstract 6.

9. Kahl B.S.; Hong F.; Williams M. et al. Results of Eastern Cooperative Oncology Group Protocol E4402 (RESORT): A Randomized Phase III Study Comparing Two Different Rituximab Dosing Strategies for Low Tumor Burden Follicular Lymphoma. Blood (ASH Annual Meeting Abstracts). 118(21): LBA-6.

10. Marcus R.; Imrie K.; Solal-Celigny P. et al. Phase III study of R-CVP compared with cyclophosphamide, vincristine, and prednisone alone in patients with previously untreated advanced follicular lymphoma. J Clin Oncol. 2008; 26(28): 4579 - 86.

11. Hiddemann W.; Kneba M.; Dreyling M. et al. Frontline therapy with rituximab added to the combination of cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) significantly improves the outcome for patients with advanced-stage follicular lymphoma compared with therapy with CHOP alone: results of a prospective randomized study of the German Low-Grade Lymphoma Study Group. Blood. 2005; 106(12): 3725 - 32.

12. Salles G.; Seymour J.F.; Offner F. et al. Rituximab maintenance for 2 years in patients with high tumour burden follicular lymphoma responding to rituximab plus chemotherapy (PRIMA): a phase 3, randomised controlled trial. Lancet. 2011; 377(9759): 42 - 51.

13. Peterson B.A.; Petroni G.R.; Frizzera G. et al. Prolonged single-agent versus combination chemotherapy in indolent follicular lymphomas: a study of the cancer and leukemia group B. J Clin Oncol. 2003; 21(1): 5 - 15.

14. Schouten H.C.; Qian W.; Kvaloy S. et al. High-dose therapy improves progression free survival and survival in relapsed follicular non-Hodgkin's lymphoma: results from the randomized European CUP trial. J Clin Oncol. 2003; 21: 3918 - 3927.

15. Ghielmini M.; Schmitz S.F.; Cogliatti S.B. et al. Prolonged treatment with rituximab in patients with follicular lymphoma significantly increases event-free survival and response duration compared with the standard weekly x 4 schedule. Blood. 2004; 103(12): 4416 - 23.

16. Martinelli G.; Schmitz S.F.; Utiger U. et al. Long-term follow-up of patients with follicular lymphoma receiving single-agent rituximab at two different schedules in trial SAKK 35/98. J Clin Oncol. 2010; 28(29): 4480 - 4.

17. Taverna C.J.; Bassi S.; Hitz F. et al. Rituximab Maintenance Treatment for a Maximum of 5 Years In Follicular Lymphoma: Safety Analysis of the Randomized Phase III Trial SAKK 35/03. Blood (ASH Annual Meeting Abstracts). 2010; 116: Abstract 1802.

18. Rigacci L.; Puccini B.; Cortelazzo S. et al. Bendamustine with or without rituximab for the treatment of heavily pretreated non-Hodgkin's lymphoma patients: A multicenter retrospective study on behalf of the Italian Lymphoma Foundation (FIL). Ann Hematol. 2012; 91(7): 1013 - 22.

19. 1. Federico M.; Luminari S.; Dondi A. et al. R-CVP vs R-CHOP vs R-FM for the initial treatment of patients with advanced stage follicular lymphoma. Preliminary results of FOLL05 IIL trial. Ann Oncol 2011; 22 (Suppl. 4): Abstract 135.

20. Nastoupil L.; Sinha R.; Byrtek M. et al. A Comparison of the Effectiveness of First-Line Chemoimmunotherapy Regimens for Follicular Lymphoma (FL) Used in the United States. Blood (ASH Annual Meeting Abstracts). 2011; 118: Abstract 97.

21. Campbell B.A.; Voss N.; Woods R. et al. Long-term outcomes for patients with limited stage follicular lymphoma: involved regional radiotherapy versus involved node radiotherapy. Cancer. 2010; 116(16): 3797 - 806.

22. Wilder R.B.; Jones D.; Tucker S.L. et al. Long-term results with radiotherapy for Stage I - II follicular lymphomas. Int J Radiat Oncol Biol Phys. 2001; 51(5): 1219 - 27.

23. Guadagnolo B.A.; Li S.; Neuberg D. Ng. A. et al. Long-term outcome and mortality trends in early-stage, Grade 1 - 2 follicular lymphoma treated with radiation therapy. Int J Radiat Oncol Biol Phys. 2006; 64(3): 928 - 34.

24. Brice P.; Bastion Y.; Lepage E. et al. Comparison in low-tumor-burden follicular lymphomas between an initial no-treatment policy, prednimustine, or interferon alfa: a randomized study from the Groupe d'Etude des Lymphomes Folliculaires. Groupe d'Etude des Lymphomes de l'Adulte. J Clin Oncol. 1997; 15(3): 1110 - 7.

25. MacManus P.M.; Hoppe R.T. Is radiotherapy curative for stage I and II low grade follicular lymphoma? Results of a long term follow-up study of patients treated at Stanford University. J Clin Oncol. 1996; 14: 1282 - 1290.

26. Coiffier B.; Osmanov E.A.; Hong X. et al. Bortezomib plus rituximab versus rituximab alone in patients with relapsed, rituximab-naive or rituximab-sensitive follicular lymphoma: a randomized phase 3 trial. Lancet Oncol. 2011; 12(8): 773 - 784.

27. Rummel M.J.; Niederle N.; Maschmeyer G. et al. Bendamustine plus rituximab versus CHOP plus rituximab as first-line treatment for patients with indolent and mantle-cell lymphomas: an open-label, multicentre, randomised, phase 3 non-inferiority trial. Lancet. 2013 Feb 19. Epub ahead of print.

28. Ardeshna K.M.; Smith P.; Norton A. et al. Long-term effect of a watch and wait policy versus immediate systemic treatment for asymptomatic advanced-stage non-Hodgkin lymphoma: a randomised controlled trial. Lancet. 2003; 362(9383): 516 - 22.

29. Нестерова Е.С.; Кравченко С.К.; Гемджян Э.Г. и соавт. Итоги десятилетнего опыта лечения больных фолликулярной лимфомой. Гематология и трансфузиология. 2012; 57(5): 3 - 8.

30. Marcus R.; Imrie K.; Belch A. et al. CVP chemotherapy plus rituximab compared with CVP as first-line treatment for advanced follicular lymphoma. Blood. 2005; 105(4): 1417 - 23.

31. Czuczman M.S.; Weaver R.; Alkuzweny B. et al. Prolonged clinical and molecular remission in patients with low-grade or follicular non-Hodgkin's lymphoma treated with rituximab plus CHOP chemotherapy: 9-year follow-up. J Clin Oncol. 2004; 22(23): 4711 - 6.

32. Kalaycio M.; Rybicki L.; Pohlman B. et al. Risk factors before autologous stem-cell transplantation for lymphoma predict for secondary myelodysplasia and acute myelogenous leukemia. J Clin Oncol. 2006; 24(22): 3604 - 10.

33. Поддубная И.В. Рецидивы фолликулярной лимфомы: проблемы и пути решения. Современная онкология. 2011; 1: 10 - 15.

34. Sebban C.; Brice R; Delarue R. et al. Impact of rituximab and/or high-dose therapy with autotransplant at time of relapse in patients with follicular lymphoma: a GELA study. J Clin Oncol 2008; 26: 3614 - 3620.

35. Fowler N.; Kahl B.S.; Lee P. et al. Bortezomib, bendamustine, and rituximab in patients with relapsed or refractory follicular lymphoma: the phase II VERTICAL study. J Clin Oncol. 2011; 29(25): 3389 - 95.

36. Davies A.; Merli F.; Mihaljevik В. et al. Pharmacokinetics and safety of subcutaneous Rituximab in follicular lymphoma (SABRINA): stage 1 analysis of a randomised phase 3 study. Lancet Oncol 2014; 15(3): 343 - 352.

37. Sehn L.H.; Chua N.S.; Mayer J. et al. GADOLIN: Primary results from a phase III study of obinutuzumab plus bendamustine compared with bendamustine alone in patients with rituximab-refractory indolent non-Hodgkin lymphoma. J Clin Oncol 2015; 33 (suppl; abstr LBA8502).